trending Market Intelligence /marketintelligence/en/news-insights/trending/oybogalyskj7ou0g7ntdng2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Apollo Endosurgery closes merger with Lpath

Brazil Pay TV Down Record Amount In 2019, With Losses Continuing In Q1'20

Case Study: Transforming Sales Enablement Data at a Global Advertising and Media Firm

Impact of COVID 19 on US Video Entertainment Trends

Key Credit Risk Factors When Assessing Banks In The Context Of COVID-19


Apollo Endosurgery closes merger with Lpath

Apollo Endosurgery Inc., a medical device company focused on less invasive therapies for the treatment of obesity, has completed its merger transaction with Lpath Inc.

Lpath was renamed Apollo Endosurgery Inc. after the closing of the deal and will start trading on the Nasdaq Global Market under the symbol APEN on Dec. 30.

Apollo's stockholders received common stock representing about 95.9% of the outstanding shares and the stockholders of Lpath retained about 4.1% of the combined company.

After a 1-for-5.5 reverse stock split, the combined company has about 10.7 million common shares outstanding.

Concurrent with the closing of the merger, certain stockholders of Apollo invested $29 million of new equity in the combined company, which is included in the 95.9% ownership of previous Apollo stockholders.